News and Events
Replimune Announces FDA Acceptance of Investigational New Drug Application for its Lead Oncolytic Immunotherapy Candidate, RP1
– September 6, 2018 at 4:01 PM EDT
‘on’ switch for
Cancer is one of the most difficult diseases to treat. It is constantly changing, requiring new and more sophisticated therapies.
Replimune is pioneering a new generation of cancer treatments called oncolytic immunotherapies. These cleverly designed therapeutics combine multiple mechanisms of action, enhancing the ability of viruses to replicate in and kill cancer cells, and generating a powerful patient-specific, systemic anti-tumor immune response.
Oncolytic immunotherapy is expected to enhance the effectiveness of immune checkpoint blockade and become the second cornerstone of immune-oncology approaches, moving beyond incremental improvement in cancer treatment to help more patients overcome their disease.